T1	p 79 116	acute invasive diarrhea in children .
T2	p 190 200	children .
T3	p 369 442	acute invasive diarrhea requiring an emergency visit in southern Israel .
T4	p 585 586	.
T5	p 699 748	acute invasive diarrhea in infants and children .
T6	p 770 857	From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years
T7	p 860 862	35
T8	p 881 932	< 3 years ) presenting with acute invasive diarrhea
T9	p 940 964	Pediatric Emergency Room
T10	p 1064 1068	= 95
T11	p 1127 1130	n =
T12	p 1194 1237	Shigella , Salmonella , Campylobacter spp .
T13	p 1256 1267	Escherichia
T14	p 1434 1443	pathogens
T15	p 1462 1472	patients :
T16	p 1494 1495	;
T17	p 1519 1520	;
T18	p 1557 1558	)
T19	p 1573 1574	.
T20	p 1680 1695	Campylobacter ,
T21	p 2006 2029	Shigella and Salmonella
T22	p 2396 2419	acute invasive diarrhea
T23	p 2423 2475	ambulatory pediatric patients requiring an emergency
T24	i 6 65	Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric
T25	i 276 320	oral antibiotics , intramuscular ceftriaxone
T26	i 650 661	formulation
T27	i 665 678	ciprofloxacin
T28	i 992 1025	either ciprofloxacin suspension (
T29	i 1029 1061	mg/kg twice a day + im placebo ;
T30	i 1071 1124	or im ceftriaxone ( 50 mg/kg/day + placebo suspension
T31	i 1194 1202	Shigella
T32	i 1242 1255	diarrheagenic
T33	i 1485 1495	Shigella ;
T34	i 1636 1644	Shigella
T35	i 1803 1832	ciprofloxacin and ceftriaxone
T36	i 1863 1876	ciprofloxacin
T37	i 2006 2014	Shigella
T38	i 2110 2125	ciprofloxacin ,
T39	i 2136 2151	; ceftriaxone ,
T40	i 2293 2311	Oral ciprofloxacin
T41	i 2355 2366	ceftriaxone
T42	o 79 102	acute invasive diarrhea
T43	o 143 151	diarrhea
T44	o 227 237	resistance
T45	o 241 258	enteric pathogens
T46	o 369 402	acute invasive diarrhea requiring
T47	o 447 460	inconvenience
T48	o 567 584	invasive diarrhea
T49	o 614 633	efficacy and safety
T50	o 699 725	acute invasive diarrhea in
T51	o 915 932	invasive diarrhea
T52	o 1175 1180	Stool
T53	o 1325 1353	Clinical response and safety
T54	o 1434 1443	pathogens
T55	o 1575 1608	Overall bacteriologic eradication
T56	o 1738 1766	Clinical cure or improvement
T57	o 1857 1876	Serum ciprofloxacin
T58	o 1985 1990	MIC90
T59	o 2056 2083	drug-related adverse events
T60	o 2194 2213	. Joint examination
T61	o 2319 2337	safe and effective
T62	o 2396 2422	acute invasive diarrhea in